Literature DB >> 9267563

Histologic and morphometric grading of gliomas. A comparative survival analysis.

I Niedermayer1, H Kolles, W Feiden.   

Abstract

OBJECTIVE: A grading system based upon morphometrically assessed quantitative parameters (HOM system) was correlated with the results of classical histologic grading (St. Anne/Mayo system [SAMS], 1988, and World Health Organization classification, 1993). Validation was done by comparison with survival data. STUDY
DESIGN: This retrospective study consisted of representative paraffin-embedded tissue sections of 139 adults who had been surgically treated for supratentorial common gliomas between 1988 and 1994. Histologic grading diagnoses were adapted to the latest standard. Computer-assisted image analysis of Ki-67 (MIB1)/ Feulgen-stained sections provided nuclear parameters appropriate to define homogeneous grades of malignancy by multivariate statistical analyses: average segment length of the minimum spanning trees (ASLMST) for the quantitation of tumor growth pattern; nuclear area percentage (NAP), reflecting cellularity; and volume-weighted mean nuclear volumes (vV) for estimating nuclear size and pleomorphism.
RESULTS: Analysis of survival data yielded no statistically significant differences between astrocytomas and oligoastroacytomas (Lee-Desu test, alpha = 5%). Furthermore, only two prognostically different grades could be established, "low grade" and "high grade" gliomas, with the first representing SAMS grades 2 and 3 and the latter SAMS grade 4 (alpha = .1%). The same applied to HOM grades (alpha = .1%). Cox regression analysis of survival data demonstrated that histologic grading diagnoses and NAP tallied best with patients' outcome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267563

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  1 in total

1.  Utility of nuclear morphometry in predicting grades of diffusely infiltrating gliomas.

Authors:  Dibyajyoti Boruah; Prabal Deb
Journal:  ISRN Oncol       Date:  2013-08-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.